Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for ASTRAZEN.BO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ASTRAZEN.BO and 80,000+ other tickers.
See exactly how ASTRAZEN.BO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ASTRAZEN.BO and 80,000+ other tickers.
AstraZeneca Pharma India Limited (AZPIL) functions as a biopharmaceutical company, involved in the manufacturing, distribution, and marketing of pharmaceutical products both within India and internationally. Its extensive product lineup includes medications for cardiovascular and diabetes conditions, marketed under brand names such as Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN. The company also offers respiratory treatments like Symbicort and FASENRA, along with a comprehensive array of oncology drugs, including LYNPARZA, Tagrisso…
No recent news available.